Liposomal azelaic acid 20% cream vs hydroquinone 4% cream as adjuvant to oral tranexamic acid in melasma: a comparative study.

Abstract

BACKGROUND:

Melasma negatively impacts patient's quality of life (QoL). Although hydroquinone 4% is the most prescribed treatment, several side effects had been reported. The traditionally used azelaic acid 20% has poor tolerability and low skin absorption rate.

AIM:

To assess the efficacy and tolerability of the liposomal form of azelaic acid 20% as an adjuvant to oral tranexamic acid in the treatment of melasma.

PATIENTS AND METHODS:

Fifty females suffering from melasma were divided into two equal groups. The first group used a liposomal form of azelaic acid 20%, and the second group used hydroquinone 4%. Oral tranexamic acid 250 mg was taken by both groups as a single oral daily dose. Melasma severity and the patient's QoL were assessed.

RESULTS:

A significant improvement of melasma was detected in females who used the liposomal form of azelaic acid 20% than those who used hydroquinone 4%. This was associated with a significant positive effect on their QoL. Furthermore, the liposomal form of azelaic acid 20% was more significantly tolerable than hydroquinone 4%.

CONCLUSION:

The use of the liposomal form of azelaic acid provides an effective and well-tolerated addition to the treatment of melasma.

• Authors: Essam M Akl
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 33 Issue 4 Pg. 2008-2013 (Jun 2022) ISSN: 1471-1753 [Electronic] England
• PMID: 33823725 (Publication Type: Journal Article)

Chemical References

• Adjuvants, Immunologic
• Dermatologic Agents
• Dicarboxylic Acids
• Emollients
• Hydroquinones
• Liposomes
• Tranexamic Acid
• azelaic acid

Topics

• Adjuvants, Immunologic
• Dermatologic Agents (adverse effects)
• Dicarboxylic Acids
• Emollients (therapeutic use)
• Female
• Humans
• Hydroquinones (therapeutic use)
• Liposomes
• Melanosis (drug therapy)
• Quality of Life
• Tranexamic Acid (therapeutic use)
• Treatment Outcome